Between March 2017 and January 2018 Dupilumab was approved in four major global regions: the US^[1], the EU^[2], Canada^[3], and Japan.^[4] Continue reading “Dupilumab (Dupixent®): NICE Publishes Positive Final Appraisal Determination” →